Journal of Veterinary Medical Science
Online ISSN : 1347-7439
Print ISSN : 0916-7250
ISSN-L : 0916-7250

この記事には本公開記事があります。本公開記事を参照してください。
引用する場合も本公開記事を引用してください。

Changes in the coagulation parameters in dogs with protein-losing enteropathy between before and after treatment
Takuro NAGAHARAKoichi OHNOItsuma NAGAOTaisuke NAKAGAWANozomu YOKOYAMAAki OHMIYuko GOTO-KOSHINOJames K. CHAMBERSKazuyuki UCHIDAHirotaka TOMIYASUHajime TSUJIMOTO
著者情報
ジャーナル オープンアクセス 早期公開

論文ID: 21-0137

この記事には本公開記事があります。
詳細
抄録

Protein-losing enteropathy (PLE) is known to induce hypercoagulability and resultant thromboembolism in dogs. We hypothesized that hypercoagulability would improve if remission was obtained in dogs with PLE after treatment. This study aimed to evaluate the changes in the coagulation parameters after treatment in dogs diagnosed with PLE. As coagulation parameters, prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, thrombin-antithrombin complex (TAT), D-dimer, and antithrombin (AT) were measured. In addition to these parameters, rotational thromboelastometry (ROTEM), which evaluates the comprehensive coagulation and fibrinolysis reactions of whole blood, was conducted and the data of clotting time (CT), clot formation time (CFT), α angle (α), maximum clot firmness (MCF) and lysis index at 60 min (LI60) were obtained. Eleven of the 14 dogs diagnosed with PLE were classified as responders to the treatment based on the changes in their plasma albumin (ALB) concentration after treatment. Significant increase in CFT and decrease of α and MCF indicating the resolution of hypercoagulability were found after treatment in responder dogs; however, there was no significant change in the coagulation and fibrinolysis parameters other than those measured by ROTEM. This study demonstrated that the hypercoagulability detected by ROTEM was significantly improved after treatment in dogs with PLE.

著者関連情報
© 2021 by the Japanese Society of Veterinary Science

This article is licensed under a Creative Commons [Attribution-NonCommercial-NoDerivatives 4.0 International] license.
https://creativecommons.org/licenses/by-nc-nd/4.0/
feedback
Top